Year in Aesthetics — 2026

AbbVie filed four material events between late April and mid-August tied to Botox/Juvéderm rebate and Allē loyalty restructuring—a rare cadence that signaled aggressive market defense. The moves included quarterly rebates tied to growth targets and program refreshes designed to lock in high-volume practices. For independent owners, the takeaway was brutal: loyalty programs now demand volume commitments to unlock rebates, compressing per-unit margins even as list prices held. Practices that couldn't scale volume faced a choice—absorb margin loss or risk losing preferred-partner status and patient access through Allē. This wasn't new, but the frequency and scale of AbbVie's moves telegraphed desperation as competitors gained traction.

Evolus delivered three consecutive quarters of positive adjusted EBITDA and raised full-year 2026 guidance after Q2 revenue hit $84.1 million. Jeuveau (prabotulinumtoxinA) gained share, driven by aggressive Evolus Rewards loyalty incentives and direct-to-medspa marketing. The company's playbook mirrored Allergan's—loyalty programs and rebates—but with lower list prices and a willingness to undercut. Perceptive Advisors took a new stake, signaling investor confidence. For owners, Evolus represented a viable alternative to Allergan's margin squeeze, though it meant navigating a second loyalty ecosystem and managing patient education around a newer brand.

Galderma reported 24.6% year-on-year growth in H1 2026 and explicitly attributed a 25% lift in aesthetics sales to GLP-1 weight-loss drug adoption. As patients on semaglutide and tirzepatide shed weight, they sought skin tightening, volume restoration, and facial rejuvenation—driving demand for Radiesse, fillers, and energy-based devices. Merz expanded Ultherapy PRIME to include knee skin laxity, signaling device makers' pivot to GLP-1-adjacent indications. For medspa owners, GLP-1 became a patient acquisition and retention lever: practices that partnered with weight-loss clinics or offered bundled skin-tightening packages captured a new revenue stream. The trend will likely persist as GLP-1 adoption deepens.

The FDA approved RHA Redensity Eye (Revance/Teoxane) for undereye hollowing, adding a new filler indication and competitive pressure on Allergan's Juvéderm. AbbVie's Botox Cosmetic in masseter muscle prominence earned FDA acceptance for a supplemental BLA, expanding the toxin's cosmetic footprint. Merz's Ultherapy PRIME knee indication and Alma Lasers' Harmony platform rollout in India signaled device makers' focus on body and emerging markets. South Korea's Big Three toxin makers (Nabota, Botulax, Medytox) posted combined Q2 revenue of ₩225.9 billion, with Nabota surpassing ₩100 billion quarterly for the first time, reflecting intense regional competition. For owners, new indications meant new revenue opportunities but also required staff training and patient education.

Steel Partners' unsolicited $16.75/share cash offer for InMode signaled private-equity appetite for profitable, recurring-revenue device platforms. InMode's installed base and service contracts made it an attractive roll-up target. While the offer's fate remained uncertain, it underscored a broader trend: device makers with strong cash flow and installed bases faced acquisition pressure, and consolidation in the device space was accelerating. For independent owners, consolidation meant fewer device vendors, potential price increases post-deal, and possible shifts in service and loyalty programs. Practices with long-term device leases or service contracts faced renegotiation risk.

Hugel Aesthetics expanded its U.S. presence with a direct sales force for Letybo and a new K-TOX campaign, signaling Korean toxin makers' commitment to U.S. market share. Allergan's Boey (rapid-onset Botox alternative) won EU approval, adding another competitor to the neurotoxin space. Xeomin's role in the neurotoxin resistance conversation highlighted patient demand for alternatives. For medspa owners, fragmentation meant more choice but also more complexity: managing multiple toxin and filler brands, loyalty programs, and pricing tiers became table stakes. Practices that could educate patients on product differences and manage inventory across brands gained an edge.